High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells.
High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells.
复制标题
DOI：
10.2147/lctt.s90694
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Chen R
中科院分区：
文献类型：
--
作者：
Tian H;Li X;Jiang W;Lv C;Sun W;Huang C;Chen R
AKR 1C 1是AKR 1C家族的成员，不仅在激素代谢中起重要作用，而且被认为参与致癌物代谢。我们前期的研究表明，AKR 1C 1在肺癌组织中的表达高于癌旁组织。小细胞肺癌（Small-cell lung cancer，SCLC）是一种特殊类型的肺癌。由于小细胞肺癌的恶性程度高、早期转移、临床标本获取困难，手术治疗通常比较困难。中华人民共和国近年来对小细胞肺癌的基础和临床研究不多。为探讨AKR 1C 1在小细胞肺癌发病中的作用机制，本研究以H446细胞为研究对象，观察AKR 1C 1对小细胞肺癌细胞增殖和迁移的影响，并利用慢病毒构建AKR 1C 1过表达和低表达细胞系。结果表明，AKR 1C 1是H446细胞增殖和迁移的重要诱导因子。AKR 1C 1促进细胞增殖，并在SCLC细胞的迁移中起重要作用。这些结果在裸鼠体内也得到了验证。结论：AKR 1C 1在小细胞肺癌的发生、发展过程中起重要作用，可能成为小细胞肺癌预后评估和治疗的独立生物标志物。
AKR1C1 is a member of the AKR1C family, which not only plays an important role in hormone metabolism but is believed to be involved in carcinogen metabolism. Our previous study demonstrated that AKR1C1 was highly expressed in lung tumor tissues as compared with the tumor-adjacent tissues. Small-cell lung cancer (SCLC) is a special type of lung cancer. Surgical treatment of SCLC is usually difficult due to the high degree of malignancy and early metastasis, and difficulty in obtaining clinical specimens. There is not much basic or clinical research on SCLC in the People’s Republic of China even in recent years. To investigate the mechanism of AKR1C1 in the pathogenesis of SCLC, the present study used H446 cell line to see whether AKR1C1 could affect the proliferation or migration of SCLC cells, and used a lentivirus to build the AKR1C1 overexpression and under-expression cell lines. The results indicated that AKR1C1 was an important inducement in the proliferation and migration of H446 cells. AKR1C1 promoted cell proliferation and played a vital role in the migration of SCLC cells. These results were also verified in nude mice in vivo. In conclusion, AKR1C1 plays an important role in the development and progression of SCLC and may represent an independent biomarker for assessment of the primary prognosis and therapy of SCLC.